XNAS
STRO
Market cap64mUSD
Jul 11, Last price
0.76USD
1D
-6.88%
1Q
26.41%
IPO
-94.92%
Name
Sutro Biopharma Inc
Chart & Performance
P/E
—
P/S
1.04
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.33%
Rev. gr., 5y
7.74%
Revenues
62m
-59.64%
Net income
-227m
L+112.99%
CFO
-192m
L+71.61%
Earnings
Aug 11, 2025
Profile
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 62,043 -59.64% | 153,731 126.84% | 67,772 9.52% | ||||||
Cost of revenue | 300,496 | 249,825 | 205,003 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (238,453) | (96,094) | (137,231) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 2,363 | 18,192 | 2,500 | ||||||
Tax Rate | |||||||||
NOPAT | (240,816) | (114,286) | (139,731) | ||||||
Net income | (227,461) 112.99% | (106,793) -10.41% | (119,204) 9.69% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 96,527 | 11,971 | 55,807 | ||||||
BB yield | -68.28% | -4.64% | -13.61% | ||||||
| Debt | |||||||||
Debt current | 7,480 | 16,901 | 17,085 | ||||||
Long-term debt | 38,828 | 52,728 | 84,589 | ||||||
Deferred revenue | 53,379 | 89,885 | |||||||
Other long-term liabilities | 195,039 | 150,808 | (89,885) | ||||||
Net debt | (270,587) | (305,989) | (232,690) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (191,540) | (111,616) | 3,549 | ||||||
CAPEX | (3,098) | (4,315) | (7,858) | ||||||
Cash from investing activities | 218,508 | (3,924) | (35,022) | ||||||
Cash from financing activities | 94,054 | 137,554 | 48,313 | ||||||
FCF | (231,928) | (107,977) | (139,204) | ||||||
| Balance | |||||||||
Cash | 316,895 | 375,618 | 302,344 | ||||||
Long term investments | 32,020 | ||||||||
Excess cash | 313,793 | 367,931 | 330,975 | ||||||
Stockholders' equity | (786,747) | (559,326) | (453,175) | ||||||
Invested Capital | 1,049,541 | 953,217 | 737,738 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 76,829 | 60,164 | 50,739 | ||||||
Price | 1.84 -57.11% | 4.29 -46.91% | 8.08 -45.70% | ||||||
Market cap | 141,366 -45.23% | 258,102 -37.04% | 409,973 -40.26% | ||||||
EV | (129,221) | (47,887) | 177,283 | ||||||
EBITDA | (231,235) | (89,278) | (131,541) | ||||||
EV/EBITDA | 0.56 | 0.54 | |||||||
Interest | 31,070 | 23,750 | 3,346 | ||||||
Interest/NOPBT | |||||||||